What is Emergent Biosolutions' stock symbol?
Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
Where is Emergent Biosolutions' stock going? Where will Emergent Biosolutions' stock price be in 2017?
5 analysts have issued 1-year target prices for Emergent Biosolutions' stock. Their forecasts range from $33.00 to $47.00. On average, they anticipate Emergent Biosolutions' stock price to reach $39.40 in the next year.
When will Emergent Biosolutions announce their earnings?
Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.
What are analysts saying about Emergent Biosolutions stock?
Here are some recent quotes from research analysts about Emergent Biosolutions stock:
According to Zacks Investment Research, "Emergent posted preliminary results for 2016 and its 2017 guidance earlier this month. While preliminary results for 2016 surpassed management’s expectations, which was provided in Dec 2016, its 2017 outlook fell short of market expectations as evident from the drop in its share price following the announcement. However, shares of the company have outperformed the broader industry so far this year. BioThrax is the key product at Emergent’s Biodefense segment and the U.S. government is the primary purchaser of its Biodefense products. The company’s follow-on contract with the CDC for BioThrax, and deals with the BARDA for BioThrax and NuThrax (the next-generation anthrax vaccine candidate) bodes well for growth. Moreover, NuThrax’s approval will be a huge boost for the company. Estimates have gone up ahead of the Q4 results. However, the company’s sole dependence on BioThrax for its top line is concerning." (2/21/2017)
Cowen and Company analysts commented, "Emergent BioSolutions pre-announced 2016 financials at the high end of the guidance." (1/9/2017)
J P Morgan Chase & Co analysts commented, "This afternoon, Emergent announced 2Q financial results, and while a great deal of focus remains on the upcoming BioThrax and NuThrax contracts, details were limited on these topics and 2016 guidance will not be reinstated until the outcomes are known. While we continue to see high probability of approval for Building 55 (Aug 15 PDUFA date), we believe the Street will need incremental clarity, particularly visibility on pricing in the next BioThrax contract and some color on expectations for the near-term delivery schedule, for the overhang on EBS shares to begin to lift. That said, this clarity is not far off, and we expect an update on both BioThrax and NuThrax by the end of September." (8/5/2016)
Who owns Emergent Biosolutions stock?
Emergent Biosolutions' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (5.00%), Aberdeen Asset Management PLC UK (3.08%), State Street Corp (3.06%), Renaissance Technologies LLC (2.18%), FIL Ltd (1.79%) and Russell Investments Group Ltd. (1.10%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Barry Labinger, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Marvin L White, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
Who sold Emergent Biosolutions stock? Who is selling Emergent Biosolutions stock?
Emergent Biosolutions' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Guggenheim Capital LLC, Numeric Investors LLC, Allianz Asset Management AG, Federated Investors Inc. PA, GSA Capital Partners LLP and Dimensional Fund Advisors LP. Company insiders that have sold Emergent Biosolutions stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Marvin L White, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
Who bought Emergent Biosolutions stock? Who is buying Emergent Biosolutions stock?
Emergent Biosolutions' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Aberdeen Asset Management PLC UK, FIL Ltd, FMR LLC, Hodges Capital Management Inc., Congress Asset Management Co. MA, A.R.T. Advisors LLC and Folger Hill Asset Management LP.
How do I buy Emergent Biosolutions stock?
Shares of Emergent Biosolutions can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Emergent Biosolutions stock cost?
One share of Emergent Biosolutions stock can currently be purchased for approximately $30.63.